Akebia Therapeutics SG&A Expense (TTM) Insights

Akebia Therapeutics Inc (AKBA)

1.33 0.00 (0.00%) USD | NASDAQ | Sep 27, 16:00

1.32 -0.01 (-0.75%) After-Hours: 20:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2013. Upgrade now.

Date	Value
June 30, 2024	100.50M
March 31, 2024	100.62M
December 31, 2023	100.24M
September 30, 2023	104.71M
June 30, 2023	113.88M
March 31, 2023	119.09M
December 31, 2022	138.36M
September 30, 2022	153.26M
June 30, 2022	167.73M
March 31, 2022	177.14M
December 31, 2021	174.14M
September 30, 2021	169.80M
June 30, 2021	163.61M
March 31, 2021	157.44M
December 31, 2020	154.10M
September 30, 2020	158.55M
June 30, 2020	152.56M
March 31, 2020	153.15M
December 31, 2019	149.46M
September 30, 2019	159.66M
June 30, 2019	135.86M
March 31, 2019	112.33M

Date	Value
December 31, 2018	87.06M
September 30, 2018	39.51M
June 30, 2018	35.88M
March 31, 2018	30.24M
December 31, 2017	27.01M
September 30, 2017	25.58M
June 30, 2017	23.78M
March 31, 2017	22.19M
December 31, 2016	22.21M
September 30, 2016	21.87M
June 30, 2016	21.00M
March 31, 2016	20.08M
December 31, 2015	18.50M
September 30, 2015	18.36M
June 30, 2015	17.23M
March 31, 2015	15.16M
December 31, 2014	14.68M
September 30, 2014	13.89M
June 30, 2014	11.75M
March 31, 2014	10.10M
December 31, 2013	7.031M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

100.24M

Minimum

Dec 2023

177.14M

Maximum

Mar 2022

143.40M

Average

153.20M

Median

SG&A Expense (TTM) Benchmarks